Form 4: Rocket Pharmaceuticals Director Pedro Granadillo Acquires Stock Options

Director Pedro Granadillo acquired stock options for Rocket Pharmaceuticals shares, vesting in June 2025.

Summary

• On June 13, 2024, Pedro Granadillo, a director of Rocket Pharmaceuticals, acquired stock options to purchase 23,944 shares of common stock at an exercise price of $22.86.
• These options will fully vest and become exercisable on June 13, 2025.
• Granadillo also acquired options to purchase 4,655 shares of common stock at an exercise price of $22.86, also vesting on June 13, 2025.
• These options were issued in lieu of $70,000 in director retainer fees.
• Following these transactions, Granadillo directly owns options for a total of 28,599 Rocket Pharmaceuticals shares.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The options granted in lieu of director fees can be seen as a way to conserve cash.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting date of the options.

Industry Context

Stock option grants to directors are a common practice in the pharmaceutical industry to align their interests with those of shareholders and incentivize long-term value creation.

Related Party Transactions

• The grant of stock options in lieu of $70,000 in director retainer fees can be considered a related party transaction.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates